Literature DB >> 9071999

Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection.

J F Emile1, N Patey, F Altare, S Lamhamedi, E Jouanguy, F Boman, J Quillard, M Lecomte-Houcke, O Verola, J F Mousnier, F Dijoud, S Blanche, A Fischer, N Brousse, J L Casanova.   

Abstract

Bacillus Calmette Guérin (BCG) is an attenuated strain of Mycobacterium bovis that is currently used as a live vaccine for human tuberculosis. Disseminated BCG infection may rarely occur following vaccination of children. In half of the cases, regarded as idiopathic, no well-defined immunodeficiency condition can account for the infection. However, the high rates of parental consanguinity and familial forms and the associated opportunistic infections with Salmonella suggest that these idiopathic BCG infections result from one or several new type(s) of inherited immune disorder(s). As an approach to the description and understanding of this newly described condition, the associated lesions were examined. Samples from 14 patients collected from a French national retrospective study were analysed. Pathological data from 22 cases reported in the world literature were also reviewed. Two types of granuloma were found. The first type (type I, tuberculoid) consisted of well-circumscribed and well-differentiated granulomas, with epithelioid and multinucleated giant cells containing very few acid-fast rods, surrounded by lymphocytes and fibrosis and occasionally with central caseous necrosis. The second type (type II, lepromatous-like) consisted of ill-defined and poorly differentiated granulomas, with few if any giant cells and lymphocytes but widespread macrophages loaded with acid-fast bacilli. Most children displayed a single type of granuloma. One half displayed type 1 lesions and the other half displayed type II lesions. There was a strong correlation between the type of granuloma and the clinical outcome. Tuberculoid lesions were associated with survival, whilst lepromatous-like lesions correlated with death. Correlation of granuloma structure with clinical outcome defines two types of idiopathic disseminated BCG infection. The phenotypic heterogeneity of the course of BCG infection reflects distinct pathogenic mechanisms and probably results from a genotypic heterogeneity of the underlying inherited immune disorder.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9071999     DOI: 10.1002/(SICI)1096-9896(199701)181:1<25::AID-PATH747>3.0.CO;2-Z

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  32 in total

1.  Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model.

Authors:  Philana Ling Lin; Amy Myers; Le'Kneitah Smith; Carolyn Bigbee; Matthew Bigbee; Carl Fuhrman; Heather Grieser; Ion Chiosea; Nikolai N Voitenek; Saverio V Capuano; Edwin Klein; JoAnne L Flynn
Journal:  Arthritis Rheum       Date:  2010-02

2.  Inherited interleukin-12 deficiency: IL12B genotype and clinical phenotype of 13 patients from six kindreds.

Authors:  Capucine Picard; Claire Fieschi; Frédéric Altare; Suliman Al-Jumaah; Sami Al-Hajjar; Jacqueline Feinberg; Stéphanie Dupuis; Claire Soudais; Ibrahim Zaid Al-Mohsen; Emmanuelle Génin; David Lammas; Dinakantha S Kumararatne; Tony Leclerc; Arash Rafii; Husn Frayha; Belinda Murugasu; Lee Bee Wah; Raja Sinniah; Michael Loubser; Emi Okamoto; Abdulaziz Al-Ghonaium; Haysam Tufenkeji; Laurent Abel; Jean-Laurent Casanova
Journal:  Am J Hum Genet       Date:  2001-12-17       Impact factor: 11.025

3.  Mycobacterium tuberculosis Infection of the placenta: a study of the early (innate) inflammatory response in two cases.

Authors:  Carlos R Abramowsky; Julie Gutman; Joseph A Hilinski
Journal:  Pediatr Dev Pathol       Date:  2012-01-19

4.  Dependence of Mycobacterium bovis BCG on anaerobic nitrate reductase for persistence is tissue specific.

Authors:  Christian Fritz; Silvia Maass; Andreas Kreft; Franz-Christoph Bange
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

5.  A computational tool integrating host immunity with antibiotic dynamics to study tuberculosis treatment.

Authors:  Elsje Pienaar; Nicholas A Cilfone; Philana Ling Lin; Véronique Dartois; Joshua T Mattila; J Russell Butler; JoAnne L Flynn; Denise E Kirschner; Jennifer J Linderman
Journal:  J Theor Biol       Date:  2014-12-09       Impact factor: 2.691

6.  Dendritic cells in chronic mycobacterial granulomas restrict local anti-bacterial T cell response in a murine model.

Authors:  Heidi A Schreiber; Paul D Hulseberg; JangEun Lee; Jozsef Prechl; Peter Barta; Nora Szlavik; Jeffrey S Harding; Zsuzsanna Fabry; Matyas Sandor
Journal:  PLoS One       Date:  2010-07-06       Impact factor: 3.240

Review 7.  A genetic perspective on granulomatous diseases with an emphasis on mycobacterial infections.

Authors:  Un-In Wu; Steven M Holland
Journal:  Semin Immunopathol       Date:  2016-01-05       Impact factor: 9.623

8.  Inherited interleukin 12 deficiency in a child with bacille Calmette-Guérin and Salmonella enteritidis disseminated infection.

Authors:  F Altare; D Lammas; P Revy; E Jouanguy; R Döffinger; S Lamhamedi; P Drysdale; D Scheel-Toellner; J Girdlestone; P Darbyshire; M Wadhwa; H Dockrell; M Salmon; A Fischer; A Durandy; J L Casanova; D S Kumararatne
Journal:  J Clin Invest       Date:  1998-12-15       Impact factor: 14.808

9.  Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection.

Authors:  J Christian J Ray; JoAnne L Flynn; Denise E Kirschner
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

10.  Differential expression of mycobacterial antigen MPT64, apoptosis and inflammatory markers in multinucleated giant cells and epithelioid cells in granulomas caused by Mycobacterium tuberculosis.

Authors:  Tehmina Mustafa; Harald G Wiker; Odd Mørkve; Lisbet Sviland
Journal:  Virchows Arch       Date:  2008-02-12       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.